US 12,134,652 B2
Human CGRP receptor binding proteins
Thomas C. Boone, Newbury Park, CA (US); David W. Brankow, Northridge, CA (US); Colin V. Gegg, Jr., Camarillo, CA (US); Shaw-Fen Sylvia Hu, Thousand Oaks, CA (US); Chadwick T. King, North Vancouver (CA); Hsieng Sen Lu, Westlake Village, CA (US); Licheng Shi, Newbury Park, CA (US); and Cen Xu, Newbury Park, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Dec. 3, 2020, as Appl. No. 17/111,453.
Application 17/111,453 is a division of application No. 15/824,827, filed on Nov. 28, 2017, abandoned.
Application 14/752,493 is a division of application No. 12/642,711, filed on Dec. 18, 2009, granted, now 9,102,731, issued on Aug. 11, 2015.
Application 15/824,827 is a continuation of application No. 14/752,493, filed on Jun. 26, 2015, granted, now 9,862,771, issued on Jan. 9, 2018.
Claims priority of provisional application 61/264,622, filed on Nov. 25, 2009.
Claims priority of provisional application 61/203,569, filed on Dec. 23, 2008.
Prior Publication US 2021/0179723 A1, Jun. 17, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); G01N 33/53 (2006.01); C12N 5/10 (2006.01); C12N 15/00 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/2869 (2013.01) [A61K 39/39533 (2013.01); A61K 39/00 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/21 (2013.01); C07K 2317/32 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C12N 5/10 (2013.01); C12N 15/00 (2013.01); C12N 15/63 (2013.01); G01N 33/53 (2013.01)] 12 Claims
 
1. A method of making an antibody that selectively inhibits human CGRP receptor as compared with human AM1, AM2, and AMY1 receptors, comprising
administering to an animal an immunogen comprising:
(i) a soluble CGRP receptor, wherein the soluble CGRP receptor is a heterodimer comprising the N-terminal extracellular domain (ECD) of human CRLR polypeptide and the ECD of human RAMP1 polypeptide,
(ii) whole cells expressing full-length human CRLR and human RAMP1 polypeptides, or
(iii) membrane extracts of the cells in (ii);
recovering antibodies from the immunized animal that bind to both human CRLR polypeptide and human RAMP1 polypeptide in the human CGRP receptor; and
selecting monoclonal antibodies that bind to an epitope formed from amino acid residues from both human CRLR polypeptide and human RAMP1 polypeptide in the human CGRP receptor.